JP2012051923A5 - - Google Patents

Download PDF

Info

Publication number
JP2012051923A5
JP2012051923A5 JP2011229609A JP2011229609A JP2012051923A5 JP 2012051923 A5 JP2012051923 A5 JP 2012051923A5 JP 2011229609 A JP2011229609 A JP 2011229609A JP 2011229609 A JP2011229609 A JP 2011229609A JP 2012051923 A5 JP2012051923 A5 JP 2012051923A5
Authority
JP
Japan
Prior art keywords
cells
use according
adipose
route
enriched population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011229609A
Other languages
Japanese (ja)
Other versions
JP2012051923A (en
JP5628131B2 (en
Filing date
Publication date
Application filed filed Critical
Priority to JP2011229609A priority Critical patent/JP5628131B2/en
Priority claimed from JP2011229609A external-priority patent/JP5628131B2/en
Publication of JP2012051923A publication Critical patent/JP2012051923A/en
Publication of JP2012051923A5 publication Critical patent/JP2012051923A5/ja
Application granted granted Critical
Publication of JP5628131B2 publication Critical patent/JP5628131B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (15)

不十分な心機能、不十分な灌流、ダメージを受けた心筋又は心臓組織再造形により特徴づけられる障害の治療のための薬剤の製造における、脂肪由来再生細胞を含む細胞の濃縮集団の使用であって、該脂肪由来再生細胞を含む細胞の濃縮集団が培養されたものではない、前記使用。   The use of a concentrated population of cells, including adipose-derived regenerative cells, in the manufacture of a medicament for the treatment of disorders characterized by inadequate cardiac function, inadequate perfusion, damaged myocardium or cardiac tissue remodeling. And said enriched population of cells comprising said adipose-derived regenerative cells is not cultured. 前記脂肪由来再生細胞を含む細胞の濃縮集団が、脂肪由来幹細胞を含む、請求項1記載の使用。   2. Use according to claim 1, wherein the enriched population of cells comprising adipose-derived regenerative cells comprises adipose-derived stem cells. 前記脂肪由来再生細胞を含む細胞の濃縮集団が、脂肪由来前駆細胞を含む、請求項1記載の使用。   2. Use according to claim 1, wherein the enriched population of cells comprising adipose-derived regenerative cells comprises adipose-derived progenitor cells. 前記障害が、心不全である、請求項1〜3のいずれか1項記載の使用。   Use according to any one of claims 1 to 3, wherein the disorder is heart failure. 前記障害が、心筋梗塞である、請求項1〜3のいずれか1項記載の使用。   The use according to any one of claims 1 to 3, wherein the disorder is myocardial infarction. 前記薬剤が、大量瞬時投与での投与用に製剤されている、請求項1〜5のいずれか1項記載の使用。   6. Use according to any one of claims 1 to 5, wherein the medicament is formulated for administration in a bolus dose. 前記薬剤が、多回投与用に製剤されている、請求項1〜5のいずれか1項記載の使用。   6. Use according to any one of claims 1 to 5, wherein the medicament is formulated for multiple administration. 前記薬剤が、少なくとも1つの血管形成因子をさらに含む、請求項1〜7のいずれか1項記載の使用。   8. Use according to any one of claims 1 to 7, wherein the medicament further comprises at least one angiogenic factor. 前記薬剤が、少なくとも1つの動脈形成因子をさらに含む、請求項1〜7のいずれか1項記載の使用。   8. Use according to any one of claims 1 to 7, wherein the medicament further comprises at least one arteriogenic factor. 前記薬剤が、1つ以上の免疫抑制剤をさらに含む、請求項1〜9のいずれか1項記載の使用。   10. Use according to any one of claims 1 to 9, wherein the medicament further comprises one or more immunosuppressive agents. 前記薬剤が、心内膜心筋経路、心外膜心筋経路、心室内経路、冠内経路、逆行性冠静脈洞経路、動脈内経路、心膜内経路又は静脈内経路を介する投与用に製剤されている、請求項1〜10記載の使用。   The drug is formulated for administration via the endocardial myocardial route, epicardial myocardial route, intraventricular route, intracoronary route, retrograde coronary sinus route, intraarterial route, intrapericardial route or intravenous route. 11. Use according to claim 1-10. 前記脂肪由来再生細胞を含む細胞の濃縮集団が、遺伝子移入によって修飾されている、請求項1〜10のいずれか1項記載の使用。   11. Use according to any one of claims 1 to 10, wherein the enriched population of cells comprising the adipose-derived regenerative cells has been modified by gene transfer. 前記脂肪由来再生細胞を含む細胞の濃縮集団が、添加物をさらに含む、請求項1〜12のいずれか1項記載の使用。   13. Use according to any one of claims 1 to 12, wherein the enriched population of cells comprising adipose-derived regenerative cells further comprises an additive. 前記添加物が、成長因子、免疫抑制剤及び細胞再凝集阻害剤からなる群から選択される、請求項13記載の使用。   14. Use according to claim 13, wherein the additive is selected from the group consisting of growth factors, immunosuppressants and cell reaggregation inhibitors. 前記脂肪由来再生細胞を含む細胞の濃縮集団が、密閉された無菌の液体／組織経路を維持するように形成されたシステムにおいて単離される、請求項1記載の使用。   The use of claim 1, wherein the enriched population of cells comprising the adipose-derived regenerative cells is isolated in a system configured to maintain a sealed, sterile fluid / tissue pathway.
JP2011229609A 2011-10-19 2011-10-19 Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions Active JP5628131B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2011229609A JP5628131B2 (en) 2011-10-19 2011-10-19 Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011229609A JP5628131B2 (en) 2011-10-19 2011-10-19 Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008513441A Division JP5210155B2 (en) 2005-05-25 2005-05-25 Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions

Publications (3)

Publication Number Publication Date
JP2012051923A JP2012051923A (en) 2012-03-15
JP2012051923A5 true JP2012051923A5 (en) 2012-07-26
JP5628131B2 JP5628131B2 (en) 2014-11-19

Family

ID=45905659

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011229609A Active JP5628131B2 (en) 2011-10-19 2011-10-19 Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions

Country Status (1)

Country Link
JP (1) JP5628131B2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9580678B2 (en) 2013-06-21 2017-02-28 The Regents Of The University Of California Microfluidic tumor tissue dissociation device
US10722540B1 (en) 2016-02-01 2020-07-28 The Regents Of The University Of California Microfluidic device and method for shear stress-induced transformation of cells
CN109564231B (en) 2016-06-08 2023-01-06 加利福尼亚大学董事会 Method and apparatus for processing tissue and cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004532202A (en) * 2001-03-15 2004-10-21 シアオ，ヨング−フー Method of therapeutically treating a clinically recognized form of a cardiac condition in a living mammal
EP2308963A3 (en) * 2001-12-07 2011-09-21 Cytori Therapeutics, Inc. System for processing lipoaspirate cells
WO2005034843A2 (en) * 2003-09-17 2005-04-21 Macropore Biosurgery Inc. Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
EP1712616B1 (en) * 2003-12-25 2009-11-11 Kanazawa University Technology Licensing Organization Ltd. Induction of myocardial cell with the use of mammalian bone marrow cell or cord blood-origin cell and fat tissue
ES2364689T3 (en) * 2005-05-25 2011-09-12 Cytori Therapeutics, Inc. PROCEDURE FOR USE OF CELLS DERIVED FROM ADIPOSE TISSUE IN THE TREATMENT OF CARDIOVASCULAR AFFECTIONS.

Similar Documents

Publication Publication Date Title
Schüttler et al. Animal models of atrial fibrillation
Wen et al. Repair mechanisms of bone marrow mesenchymal stem cells in myocardial infarction
Rahm et al. Role of ion channels in heart failure and channelopathies
Charwat et al. Role of adult bone marrow stem cells in the repair of ischemic myocardium: current state of the art
Nakatani et al. Tranilast prevents atrial remodeling and development of atrial fibrillation in a canine model of atrial tachycardia and left ventricular dysfunction
ES2530681T3 (en) Floating pharmaceutical controlled release compositions
JP2012051923A5 (en)
Chin et al. Intramyocardial and intracoronary autologous bone marrow-derived mesenchymal stromal cell treatment in chronic severe dilated cardiomyopathy
Collins et al. Cell therapy in myocardial infarction
Alawami et al. Atrial fibrillation after cardiac surgery: prevention and management: the Australasian experience
Haller et al. The role of regenerative therapy in the treatment of right ventricular failure: a literature review
Lee et al. Combined St. Thomas and histidine-tryptophan-ketoglutarat solutions for myocardial preservation in heart transplantation patients
Muhll et al. Applying standard therapies to new targets: the use of ACE inhibitors and B-blockers for heart failure in adults with congenital heart disease
Afzal et al. Cardiosphere-derived cells demonstrate metabolic flexibility that is influenced by adhesion status
Xiao et al. Pathogenesis of pulmonary hypertension caused by left heart disease
Pytel et al. Ventricular fibrillation following autologous intramyocardial cell therapy for inherited cardiomyopathy
Cosentino et al. Rationale, experimental data, and emerging clinical evidence on early and preventive use of levosimendan in patients with ventricular dysfunction
Choudry et al. Stem cell therapy in cardiology
Monsanto et al. Enhanced myocardial repair with CardioClusters
Tariq et al. Use of stem cells in ischemic heart disease
Ghodsizad et al. Transplanted human cord blood-derived unrestricted somatic stem cells preserve high-energy reserves at the site of acute myocardial infarction
Silveira Filho et al. Trimetazidine as cardioplegia addictive without pre-treatment does not improve myocardial protection: study in a swine working heart model
Dayan et al. Cardiac rehabilitation after coronary artery bypass surgery
Bodiga et al. Use of ginseng to reduce post-myocardial adverse myocardial remodeling: applying scientific principles to the use of herbal therapies
Fominskiy et al. eReply. Phosphocreatine in cardiovascular disease: how can we relate the evidence to clinical practice?